Skip to main content
. 2025 Jul 9;16:1607619. doi: 10.3389/fimmu.2025.1607619

Table 1.

Characteristics of 285 PTLD patients and 28 healthy controls with PLQS data, flow cytometry, and/or cytokine/chemokine data available. Extended demographic information, including by patient subgroup, is available in Supplementary Data .

Variable PTLD Mean PTLD Median PTLD IQR PTLD %Missing HC Mean HC Median HC IQR HC %Missing
Age (yrs) 48.26 49 22 . 42.29 37 26.75 .
Male (%) 56.5 . . . 39.3 . . .
White, non-Hispanic (%) 91.2 . . . 64.3 . . .
BMI 27.0 25.82 6.89 7.38 27.57 25.78 5.78 75
High-Income (> $100k/yr) (%) 56.1 . . . 32.1 . . .
STTT Seropositive (%) 85.1 . . 1.05 . . . .
EM Rash (%) 39.6 . . . . . . .
Time post-infection at enrollment (years) 3.20 1.73 3.45 . . . . .
Time from inf. to treatment (days) 208.9 22 123 . . . . .
Total time on antibiotics (days) 102.85 51 69.25 . . . . .
Lyme arthritis (initial inf.) (%) 10.66 . . . . . . .
Lyme carditis (initial inf.) (%) 1.47 . . . . . . .
Neuroborreliosis (initial inf.) (%) 6.62 . . . . . . .